These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22399309)

  • 21. Cardiovascular risk in rheumatoid arthritis.
    Nurmohamed MT
    Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rheumatoid arthritis (updated Current Care guideline)].
    Hakala M; Hannonen P; Helve T; Korpela M; Mattila K; Möttönen T; Varis T;
    Duodecim; 2009; 125(19):2131-2. PubMed ID: 19938416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis.
    Shen J; Shang Q; Tam LS
    Transl Res; 2016 Jan; 167(1):138-51. PubMed ID: 26051628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiovascular disorders and rheumatic disease].
    Villa-Forte A; Mandell BF
    Rev Esp Cardiol; 2011 Sep; 64(9):809-17. PubMed ID: 21763053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
    Toussirot É
    Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS; Taylor WJ;
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
    Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
    J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
    Nasir A; Greenberg JD
    Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current concepts and new developments in the treatment of psoriatic arthritis.
    Pipitone N; Kingsley GH; Manzo A; Scott DL; Pitzalis C
    Rheumatology (Oxford); 2003 Oct; 42(10):1138-48. PubMed ID: 12810935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular disease in rheumatoid arthritis.
    Kaplan MJ
    Curr Opin Rheumatol; 2006 May; 18(3):289-97. PubMed ID: 16582694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.
    Ferraccioli G; Gremese E
    Autoimmun Rev; 2004 Jun; 3(4):261-6. PubMed ID: 15246021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease modification and cardiovascular risk reduction: two sides of the same coin?
    Hall FC; Dalbeth N
    Rheumatology (Oxford); 2005 Dec; 44(12):1473-82. PubMed ID: 16076883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of cardiovascular risk factors].
    Krüger K
    Z Rheumatol; 2016 Mar; 75(2):173-80; quiz 181-2. PubMed ID: 26924198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review.
    Verhoeven F; Prati C; Chouk M; Demougeot C; Wendling D
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1105-1112. PubMed ID: 34006152
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular disease and rheumatoid arthritis: an update.
    Charles-Schoeman C
    Curr Rheumatol Rep; 2012 Oct; 14(5):455-62. PubMed ID: 22791398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of publications evaluating opioid use in patients with inflammatory rheumatic disease.
    Anastasiou C; Yazdany J
    Curr Opin Rheumatol; 2022 Mar; 34(2):95-102. PubMed ID: 35044328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.
    Chighizola C; Schioppo T; Ingegnoli F; Meroni PL
    Curr Vasc Pharmacol; 2012 Sep; 10(5):639-46. PubMed ID: 22272912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.